UCB makes case for wider Bimzelx label in USA

10 November 2023

Belgium’s largest pharma company, UCB (Euronext: UCB), has announced new long-term data from the Bimzelx (bimekizumab) Phase IIb study BE AGILE and its open label extension (OLE).

Patients with ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis, treated with the interleukin (IL)-17A and IL-17F inhibitor, showed sustained improvements in signs and symptoms, disease activity, physical function and health-related quality of life for up to five years, with a consistent safety profile through five years of treatment.

"There is a need for additional treatment options for people living with AS since many people do not achieve long-term disease control"Bimzelx is not approved in the USA for the treatment of AS, though it did l ast month gain approval for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK